Morgan E. Milton

Dr. Morgan E. Milton

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Journal of Molecular Biology
Verified
Journal Article
Closed access
GDG. Logan Draughn
G. Logan Draughn
MMMorgan E. Milton
Morgan E. Milton
EFErik A. Feldmann
Erik A. Feldmann
BBBenjamin Bobay
Benjamin Bobay
BRBraden M. Roth
Braden M. Roth
JCJohn Cavanagh
John Cavanagh

5 September 2019 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MMMorgan E. Milton
Morgan E. Milton
GDG. Logan Draughn
G. Logan Draughn
BBBenjamin Bobay
Benjamin Bobay
SSSean D. Stowe
Sean D. Stowe
AOAndrew L. Olson
Andrew L. Olson
JCJohn Cavanagh
John Cavanagh

16 December 2022 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MMMorgan E. Milton
Morgan E. Milton
JCJohn Cavanagh
John Cavanagh

1 August 2016 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
MMMorgan E. Milton
Morgan E. Milton
SNScott W. Nelson
Scott W. Nelson

13 February 2018 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
MMMorgan E. Milton
Morgan E. Milton
BMBradley M. Minrovic
Bradley M. Minrovic
DHDanni L. Harris
Danni L. Harris
BKBrian Kang
Brian Kang
DJDavid Jung
David Jung
JCJohn Cavanagh
John Cavanagh
2-aminoimidazole (2-AI) compounds inhibit the formation of bacterial biofilms, disperse preformed biofilms, and re-sensitize multidrug resistant bacteria to antibiotics. 2-AIs have previously been shown to interact with bacterial response regulators, but the mechanism of interaction is still unknown. Response regulators are one part of two-component systems (TCS). TCSs allow cells to respond to changes in their environment, and are used to trigger quorum sensing, virulence factors, and antibiotic resistance. Drugs that target the TCS signaling process can inhibit pathogenic behavior, making this a potent new therapeutic approach that has not yet been fully exploited. We previously laid the groundwork for the interaction of the Acinetobacter baumannii response regulator BfmR with an early 2-AI derivative. Here, we further investigate the response regulator/2-AI interaction and look at a wider library of 2-AI compounds. By combining molecular modeling with biochemical and cellular studies, we expand on a potential mechanism for interaction between response regulators and 2-AIs. We also establish that Francisella tularensis/novicida, encoding for only three known response regulators, can be a model system to study the interaction between 2-AIs and response regulators. We show that knowledge gained from studying Francisella can be applied to the more complex A. baumannii system, which contains over 50 response regulators. Understanding the impact of 2-AIs on response regulators and their mechanism of interaction will lead to the development of more potent compounds that will serve as adjuvant therapies to broad-range antibiotics.

29 July 2017 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
MMMorgan E. Milton
Morgan E. Milton
CAC. Leigh Allen
C. Leigh Allen
EFErik A. Feldmann
Erik A. Feldmann
BBBenjamin Bobay
Benjamin Bobay
DJDavid K. Jung
David K. Jung
JCJohn Cavanagh
John Cavanagh
Summary: With antibiotic resistance increasing at alarming rates, targets for new antimicrobial therapies must be identified. A particularly promising target is the bacterial two‐component system. Two‐component systems allow bacteria to detect, evaluate and protect themselves against changes in the environment, such as exposure to antibiotics and also to trigger production of virulence factors. Drugs that target the response regulator portion of two‐component systems represent a potent new approach so far unexploited. Here, we focus efforts on the highly virulent bacterium Francisella tularensis tularensis. Francisella contains only three response regulators, making it an ideal system to study. In this study, we initially present the structure of the N‐terminal domain of QseB, the response regulator responsible for biofilm formation. Subsequently, using binding assays, computational docking and cellular studies, we show that QseB interacts with2‐aminoimidazole based compounds that impede its function. This information will assist in tailoring compounds to act as adjuvants that will enhance the effect of antibiotics.